BioWa opens POTELLIGENT® Technology license to customers for creating POTELLIGENT® cell lines

January 11, 2016, La Jolla, California USA  BioWa, Inc. (President and CEO: Yasunori Yamaguchi, Ph.D.; Headquartered in La Jolla, California, USA, “BioWa”) today announced that it has opened its POTELLIGENT® Technology licenses to allow customers to create POTELLIGENT® cell lines. The POTELLIGENT® Technology licenses have been available with BioWa’s proprietary POTELLIGENT® CHO DG44 Cell Line, or the POTELLIGENT® CHOK1SV™ Cell Line, jointly owned by BioWa and Lonza. The offer announced today adds a new licensing option from BioWa, which allows a customer to create a POTELLIGENT® cell line (an alpha 1-6, fucosyltransferase (FUT8) knockout cell line) to produce POTELLIGENT® antibodies.

“POTELLIGENT® Technology has been recognized as a global standard technology to enhance antibody-dependent cellular cytotoxicity (ADCC) in therapeutic antibodies through our 13-year business track record” said, Yasunori Yamaguchi, President and CEO of BioWa. “The new option could create another value to a customer who wishes to produce POTELLIGENT® antibodies by a cell line of their own choice, which would increase the chances of success in research, development and manufacturing of therapeutic antibodies by our customers”.

In parallel with the new offer, BioWa will actively continue to license the POTELLIGENT® Technology with the POTELLIGENT® CHO DG44 Cell Line and the POTELLIGENT® CHOK1SV™ Cell Line. For more information on POTELLIGENT® Technology, please visit our websites at http://www.kyowa-kirin.com/biowa/out-licensing/technologies/index.html, and http://www.potelligent.com/

or inquire from our Licensing Contact Form at http://www.kyowa-kirin.com/biowa/contact_us/index.html

About POTELLIGENT® Technology
POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are currently being investigated in human clinical trials. On May 29, 2012, Kyowa Hakko Kirin launched POTELIGEO®, (Mogamulizumab) a POTELLIGENT® Antibody for patients with relapsed or refractory CCR4-positive Adult T-cell Leukemia-Lymphoma (http://www.kyowa-kirin.com/)
This milestone event represents a critical validation point for the POTELLIGENT® Technology.

About BioWa
BioWa, headquartered in La Jolla, California, the United States, is a wholly owned subsidiary of Kyowa Hakko Kirin, Co, Ltd. (President and CEO: Nobuo Hanai, Ph.D.) a leading biopharmaceutical company in Japan, and is the exclusive worldwide licensor of the AccretaMab® platform. The AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and Complement-Dependent Cytotoxicity (CDC) activities. BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promoting ADCC/CDC-enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit our web site at www.kyowa-kirin.com/biowa. POTELIGEO®, POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the registered trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

BioWa Contact Information
Yasunori Yamaguchi, Ph.D. President and CEO
Tel +1 858 952 7200
Contact form http://www.kyowa-kirin.com/biowa/contact_us/index.html